[{"id":"43707759-e80d-422e-92b4-48c987e89ea1","acronym":"CARMEN-LC06","url":"https://clinicaltrials.gov/study/NCT05245071","created_at":"2022-02-17T18:22:23.864Z","updated_at":"2024-07-02T16:34:59.736Z","phase":"Phase 2","brief_title":"Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA","source_id_and_acronym":"NCT05245071 - CARMEN-LC06","lead_sponsor":"Sanofi","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tusamitamab ravtansine (SAR408701)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 03/06/2024","primary_completion_date":" 03/06/2024","study_txt":" Completion: 09/02/2024","study_completion_date":" 09/02/2024","last_update_posted":"2024-05-31"},{"id":"8124bd6b-d159-4e19-8e69-ca6cc82c95bb","acronym":"CARMEN-LC05","url":"https://clinicaltrials.gov/study/NCT04524689","created_at":"2021-01-18T21:40:16.688Z","updated_at":"2024-07-02T16:35:02.714Z","phase":"Phase 2","brief_title":"Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC","source_id_and_acronym":"NCT04524689 - CARMEN-LC05","lead_sponsor":"Sanofi","biomarkers":" CEACAM5","pipe":" | ","alterations":" PD-L1 expression","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • tusamitamab ravtansine (SAR408701)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 10/26/2020","start_date":" 10/26/2020","primary_txt":" Primary completion: 03/12/2024","primary_completion_date":" 03/12/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-05-17"},{"id":"63f076a8-74c5-4394-bd30-306e1c08b667","acronym":"CARMEN-LC04","url":"https://clinicaltrials.gov/study/NCT04394624","created_at":"2021-01-18T21:12:33.631Z","updated_at":"2024-07-02T16:35:06.670Z","phase":"Phase 2","brief_title":"Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)","source_id_and_acronym":"NCT04394624 - CARMEN-LC04","lead_sponsor":"Sanofi","biomarkers":" CEACAM5","pipe":"","alterations":" ","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Cyramza (ramucirumab) • tusamitamab ravtansine (SAR408701)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 08/31/2020","start_date":" 08/31/2020","primary_txt":" Primary completion: 03/06/2023","primary_completion_date":" 03/06/2023","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-05-01"},{"id":"0fe1e661-e6ba-4ae8-8932-832c728d7b6b","acronym":"INTRUSION","url":"https://clinicaltrials.gov/study/NCT05703555","created_at":"2023-01-30T18:59:46.055Z","updated_at":"2024-07-02T16:35:17.295Z","phase":"Phase 2","brief_title":"INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701","source_id_and_acronym":"NCT05703555 - INTRUSION","lead_sponsor":"Erasmus Medical Center","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tusamitamab ravtansine (SAR408701)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/16/2024","start_date":" 02/16/2024","primary_txt":" Primary completion: 02/16/2024","primary_completion_date":" 02/16/2024","study_txt":" Completion: 02/16/2024","study_completion_date":" 02/16/2024","last_update_posted":"2024-02-28"},{"id":"e483da09-1bb6-46ab-aa2e-93521565268b","acronym":"CARMEN-LC03","url":"https://clinicaltrials.gov/study/NCT04154956","created_at":"2021-01-18T20:16:25.438Z","updated_at":"2024-07-02T16:35:20.207Z","phase":"Phase 3","brief_title":"SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients","source_id_and_acronym":"NCT04154956 - CARMEN-LC03","lead_sponsor":"Sanofi","biomarkers":" CEACAM5","pipe":"","alterations":" ","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • tusamitamab ravtansine (SAR408701)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 411","initiation":"Initiation: 02/06/2020","start_date":" 02/06/2020","primary_txt":" Primary completion: 09/22/2023","primary_completion_date":" 09/22/2023","study_txt":" Completion: 08/26/2026","study_completion_date":" 08/26/2026","last_update_posted":"2024-02-08"},{"id":"e833311f-dab8-4bb9-9ede-64a73ab5dc32","acronym":"CARMEN-GC01","url":"https://clinicaltrials.gov/study/NCT05071053","created_at":"2021-10-07T12:53:10.291Z","updated_at":"2024-07-02T16:35:20.173Z","phase":"Phase 2","brief_title":"Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer","source_id_and_acronym":"NCT05071053 - CARMEN-GC01","lead_sponsor":"Sanofi","biomarkers":" CEACAM5","pipe":"","alterations":" ","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cyramza (ramucirumab) • tusamitamab ravtansine (SAR408701)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 11/16/2021","start_date":" 11/16/2021","primary_txt":" Primary completion: 06/23/2023","primary_completion_date":" 06/23/2023","study_txt":" Completion: 06/28/2024","study_completion_date":" 06/28/2024","last_update_posted":"2024-02-08"},{"id":"d536d339-1d05-4a52-ba58-80326ad5a6b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05849246","created_at":"2023-05-08T15:04:09.908Z","updated_at":"2024-07-02T16:35:48.788Z","phase":"Phase 2","brief_title":"The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)","source_id_and_acronym":"NCT05849246","lead_sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","biomarkers":" BRAF • ALK • CEACAM5","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF • ALK • CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Tyvyt (sintilimab) • pemetrexed • tusamitamab ravtansine (SAR408701)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 05/30/2023","start_date":" 05/30/2023","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-05-08"},{"id":"2855f339-9b0d-49e8-bb3f-80feb3b6dbdc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03324113","created_at":"2021-01-18T16:24:55.664Z","updated_at":"2024-07-02T16:35:58.002Z","phase":"Phase 1","brief_title":"Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors","source_id_and_acronym":"NCT03324113","lead_sponsor":"Sanofi","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tusamitamab ravtansine (SAR408701)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 10/17/2017","start_date":" 10/17/2017","primary_txt":" Primary completion: 11/18/2022","primary_completion_date":" 11/18/2022","study_txt":" Completion: 12/26/2022","study_completion_date":" 12/26/2022","last_update_posted":"2023-01-09"}]